Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper session: CNS tumours

279O - ctDNA detection in cerebrospinal fluid and concordance with the primary tumor in a multicenter prospective study of patients with glioma


09 Sep 2022


Proffered Paper session: CNS tumours


Clinical Research;  Pathology/Molecular Biology;  Translational Research;  Molecular Oncology

Tumour Site

Central Nervous System Malignancies


Santiago Cabezas-Camarero


Annals of Oncology (2022) 33 (suppl_7): S122-S135. 10.1016/annonc/annonc1047


S. Cabezas-Camarero1, R. Pérez-Alfayate2, V. García-Barberán1, M. Gandía3, P. García-Feijóo3, I. López-Cade1, I. Casado-Fariñas4, N. Cerón4, M.J. Sotelo Lezama5, P. Pérez Segura1

Author affiliations

  • 1 Medical Oncology Department, Hospital Clinico Universitario San Carlos, 28040 - Madrid/ES
  • 2 Neurosurgery, Hospital Clinico Universitario San Carlos, 28040 - Madrid/ES
  • 3 Neurosurgery, Hospital Universitario La Paz, 28046 - Madrid/ES
  • 4 Pathology, Hospital Clinico Universitario San Carlos, 28040 - Madrid/ES
  • 5 Medical Oncology Department, Hospital Maria Auxiliadora, 15046 - Lima/PE


Login to access the resources on OncologyPRO.

Abstract 279O


Gliomas are the most common primary brain tumors, but there are currently many limitations for the implementation of liquid biopsy in this disease. Cerebrospinal fluid (CSF) is emerging as the most reliable reservoir for ctDNA analysis, although evidence is still limited.


Prospective study of patients with gliomas diagnosed at Hospital Clinico Universitario San Carlos and Hospital Universitario La Paz (Madrid, Spain). High throughput next generation sequencing (NGS) using a customized gene panel (Illumina, Inc.) of 8 genes (IDH1, IDH2, ATRX, TP53, PTEN, PIK3CA, EGFR, BRAF) was used in paired CSF and FFPE and/or fresh tumor samples, and run in an Illumina Miseq instrument (Illumina, Inc.). Only confirmed pathogenic mutations were considered as valid and are reported here. Mutation concordance occurred when the same pathogenic gene variants were detected in tumor and CSF.


Between February 2017 and March 2020, 31 glioma patients (pts) were enrolled in which 2-5 ml of CSF were collected intraoperatively prior to surgical manipulation of the tumor. M:F ratio: 22:9. Median age 51 (Min-Max: 20-78). CSF collected at new diagnosis (n=22); relapse (n=9). WHO 5th Ed: IDHMUT astrocytoma (n=9), IDHMUT oligodendroglioma (n=6), IDHWT glioblastoma (n=16). CSF-ctDNA-positive: 18/31 (58%). CSF-ctDNA-negative: 13/31 (42%). No. of mutations in CSF: 1 (9/18), 2 (7/18), 3 (2/18). Frequency of CSF-ctDNA mutated genes: EGFR (8/18: 44%), PTEN (7/18: 39%), TP53 (6/18: 33%), IDH1 (4/18: 22%), PIK3CA (4/18: 22%). Tumor-CSF mutation concordance: 15/18 (83%). After a median follow-up since CSF collection of 20 months (m) (Min-Max: 0-57), median OS was not reached (NR) (95%CI NR-NR). No correlation was found between detection of ctDNA in CSF and distance from closest CSF reservoir, tumor size or IDH status.


CSF is a reliable reservoir for ctDNA analyses in patients with gliomas. Larger, prospective studies should be conducted in order to refine the potential role of liquid biopsy in this disease.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Study funded thanks to the BECA GEINO 2016 from Grupo Español de Investigación en Neuro-Oncología (GEINO).


S. Cabezas-Camarero: Financial Interests, Personal, Invited Speaker: BMS, Merck Serono, MSD; Financial Interests, Personal, Expert Testimony: MSD, BMS, Merck Serono; Financial Interests, Personal, Advisory Board: Merck Serono; Financial Interests, Institutional, Funding: Merck Serono. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.